Literature DB >> 11871387

Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia.

Jordi Esteve, Neus Villamor, Dolors Colomer, Emil Montserrat.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 11871387     DOI： 10.1182/blood.v99.5.1873

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  2 in total

1.  Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.

Authors:  Lucia Farina; Cristiana Carniti; Anna Dodero; Antonio Vendramin; Anna Raganato; Francesco Spina; Francesca Patriarca; Franco Narni; Fabio Benedetti; Attilio Olivieri; Paolo Corradini
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

Review 2.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.